110 related articles for article (PubMed ID: 11821743)
1. A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease.
Sculley TB; Buck M; Gabrielli B; Parsons PG; Krauer KG
Transplantation; 2002 Jan; 73(2):271-9. PubMed ID: 11821743
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
[TBL] [Abstract][Full Text] [Related]
3. Restoring cellular differentiatin in posttransplant lymphoproliferative disease.
Amlot PL
Transplantation; 2002 Jan; 73(2):163-5. PubMed ID: 11821723
[No Abstract] [Full Text] [Related]
4. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.
Markasz L; Stuber G; Flaberg E; Jernberg AG; Eksborg S; Olah E; Skribek H; Szekely L
BMC Cancer; 2006 Nov; 6():265. PubMed ID: 17101045
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors.
Rea D; Delecluse HJ; Hamilton-Dutoit SJ; Marelle L; Joab I; Edelman L; Finet JF; Raphael M
Ann Oncol; 1994; 5 Suppl 1():113-6. PubMed ID: 8172807
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
7. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.
Kawada J; Zou P; Mazitschek R; Bradner JE; Cohen JI
J Biol Chem; 2009 Jun; 284(25):17102-17109. PubMed ID: 19386607
[TBL] [Abstract][Full Text] [Related]
8. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
[TBL] [Abstract][Full Text] [Related]
9. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
[TBL] [Abstract][Full Text] [Related]
10. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
11. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.
Majewski M; Korecka M; Kossev P; Li S; Goldman J; Moore J; Silberstein LE; Nowell PC; Schuler W; Shaw LM; Wasik MA
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4285-90. PubMed ID: 10759564
[TBL] [Abstract][Full Text] [Related]
12. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus modulates host cell microRNA-194 to promote IL-10 production and B lymphoma cell survival.
Harris-Arnold A; Arnold CP; Schaffert S; Hatton O; Krams SM; Esquivel CO; Martinez OM
Am J Transplant; 2015 Nov; 15(11):2814-24. PubMed ID: 26147452
[TBL] [Abstract][Full Text] [Related]
14. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
Johnson LR; Nalesnik MA; Swerdlow SH
Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
16. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
17. Cancer-infection interface in children after transplantation: posttransplant lymphoproliferative disorder and Epstein-Barr virus infection.
Fujieda M; Hattori M
Curr Opin Organ Transplant; 2013 Oct; 18(5):549-54. PubMed ID: 23995375
[TBL] [Abstract][Full Text] [Related]
18. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders.
Smir BN; Hauke RJ; Bierman PJ; Gross TG; d'Amore F; Anderson JR; Greiner TC
Lab Invest; 1996 Oct; 75(4):575-88. PubMed ID: 8874388
[TBL] [Abstract][Full Text] [Related]
20. Simiao Qingwen Baidu decoction inhibits Epstein-Barr virus-induced B lymphoproliferative disease and lytic viral replication.
Yang X; Liu L; Zhang H; Sun X; Yan Y; Ran R
Pharm Biol; 2021 Dec; 59(1):741-747. PubMed ID: 34155950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
